Cronos Group (TSX:CRON) Expands International Focus, Is The Stock Still Undervalued?
Cronos Group (TSX:CRON) drew fresh attention after its shares rose 3.59% on 16 September 2026, as investors reacted to news related to its global cannabis strategy and operational execution.
That CA$4.72 share price now sits on top of a 90 day share price return of 23.88% and a year to date share price gain of 27.91%. The 3 year total shareholder return of 63.89% suggests Cronos Group’s momentum has been building rather than fading.
Scan beyond Cronos Group and see how other regulated cannabis players with building momentum stack up in our curated list of 9 high quality undiscovered gems.
Cronos Group now trades only modestly below the average analyst target, yet screens on some metrics at a much steeper discount to estimated fair value. Is the market’s caution about this cannabis player misplaced or well earned?
Most Popular Narrative: 1% Overvalued
Cronos Group last closed at CA$4.72, very close to the narrative fair value of CA$4.68. This reflects a detailed model using a 6.35% discount rate and specific assumptions about margins, revenue and future earnings.
Strategic investment capacity, highlighted by a strong balance sheet with $834 million in cash and zero debt, enables Cronos to pursue further product innovation, international expansion, and value-accretive partnerships, positively impacting net margins and future earnings growth. Reduced operating expenses and a strategic revenue mix shift toward higher-priced international markets are leading to material improvements in adjusted EBITDA and gross margin, setting the stage for a return to sustained profitability.
See why 10 investors see Cronos Group as 1% overvalued.
Result: Fair Value of CA$4.68 (OVERVALUED)
Still, the Cronos Group story could be knocked off course if regulatory changes in key markets disappoint, or if operating costs remain higher than the current gross profit base.
Find out about the key risks to this Cronos Group narrative.
Another View: Cash Flow Signals On Cronos Group
While the analyst narrative pegs Cronos Group as roughly 1% overvalued at CA$4.68, the Simply Wall St DCF model paints a very different picture. On that approach, CRON at CA$4.72 trades around 42% below an estimated future cash flow value of CA$8.13, which frames the same business as materially undervalued. Which lens do you trust more for a long term decision?
Our DCF framework lays out every assumption behind that gap, so you can judge the inputs rather than just the headline number. Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Cronos Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 3 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If the mixed signals around Cronos Group leave you undecided, move quickly to review the full picture yourself and weigh both sides. To see the balance of caution and optimism in one place, start with the 3 key rewards and 1 important warning sign.
Looking for more ideas beyond Cronos Group?
Do not stop your research with Cronos Group. Broaden your watchlist with fresh ideas that match your style, risk appetite, and income goals.
- Target potential upside early and scan through quality small caps using the Simply Wall St screener built around 21 elite penny stocks with strong financials.
- Prioritise value and financial strength by reviewing companies that combine sensible pricing with robust fundamentals through the carefully filtered 3 high quality undervalued stocks.
- Focus on resilience first and seek out businesses with steadier profiles and measured risk scores through the hand picked 8 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com